FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000807900> ?p ?o ?g. }

• W2000807900 endingPage "543" @default.
• W2000807900 startingPage "531" @default.
• W2000807900 abstract "1. After a hiatus of over 20 years, several new antiepileptic drugs (vigabatrin, lamotrigine, gabapentin, oxcarbazepine, topiramate, felbamate, zonisamide and tiagabine) have reached or approached the registration phase. 2. Compared with older agents, many new drugs exhibit simpler pharmacokinetics. This is especially true for vigabatrin and gabapentin, which are renally eliminated and have a low interaction potential. 3. Unlike most of the older agents, vigabatrin, lamotrigine, gabapentin and tiagabine are devoid of significant enzyme inducing or inhibiting properties. Topiramate, oxcarbazepine and felbamate may induce the metabolism of steroid oral contraceptives. In addition, felbamate also acts as a metabolic inhibitor. 4. To date, the efficacy of new drugs has been evaluated extensively only under add-on conditions in patients with partial seizures (with or without secondary generalization) refractory to conventional treatment. However, there is evidence that lamotrigine, zonisamide, felbamate and, possibly, topiramate may also be effective in generalized epilepsies. 5. In placebo-controlled studies, typically between 15 and 40% of patients with difficult-to-treat partial epilepsy have shown an improvement (defined as a 50% or greater decrease in seizure frequency) after addition of a new drug. Only a small minority of these patients achieved complete seizure control. 6. Compared with older agents, some of the new drugs may have a better tolerability profile. Felbamate, however, has been associated with a high risk of aplastic anaemia and hepatotoxicity. 7. At present, the main use of the new agents is in patients refractory to first-line drugs such as carbamazepine or valproate, and further studies are required to characterize their activity spectrum as well as their potential value in monotherapy. In most patients, new drugs cannot be recommended for first-line use until evidence is obtained that potential advantages in tolerability or ease of use outweigh the drawback of their high cost." @default.
• W2000807900 created "2016-06-24" @default.
• W2000807900 creator A5040883137 @default.
• W2000807900 date "1996-11-01" @default.
• W2000807900 modified "2023-10-12" @default.
• W2000807900 title "The new generation of antiepileptic drugs: advantages and disadvantages" @default.
• W2000807900 cites W1732466172 @default.
• W2000807900 cites W1964465959 @default.
• W2000807900 cites W1965450907 @default.
• W2000807900 cites W1966649086 @default.
• W2000807900 cites W1974869057 @default.
• W2000807900 cites W1975656751 @default.
• W2000807900 cites W1978139201 @default.
• W2000807900 cites W1980525228 @default.
• W2000807900 cites W1981331912 @default.
• W2000807900 cites W1981581965 @default.
• W2000807900 cites W1986129279 @default.
• W2000807900 cites W1990837904 @default.
• W2000807900 cites W1993013394 @default.
• W2000807900 cites W1996143761 @default.
• W2000807900 cites W1996172988 @default.
• W2000807900 cites W1998768292 @default.
• W2000807900 cites W2000630787 @default.
• W2000807900 cites W2002387779 @default.
• W2000807900 cites W2010272426 @default.
• W2000807900 cites W2010494079 @default.
• W2000807900 cites W2011370807 @default.
• W2000807900 cites W2011469995 @default.
• W2000807900 cites W2012015292 @default.
• W2000807900 cites W2019006710 @default.
• W2000807900 cites W2019329926 @default.
• W2000807900 cites W2026563311 @default.
• W2000807900 cites W2033170392 @default.
• W2000807900 cites W2039100312 @default.
• W2000807900 cites W2039674635 @default.
• W2000807900 cites W2043559003 @default.
• W2000807900 cites W2046577332 @default.
• W2000807900 cites W2050503366 @default.
• W2000807900 cites W2051427702 @default.
• W2000807900 cites W2052628140 @default.
• W2000807900 cites W2054779080 @default.
• W2000807900 cites W2061854958 @default.
• W2000807900 cites W2065145597 @default.
• W2000807900 cites W2077964666 @default.
• W2000807900 cites W2079515082 @default.
• W2000807900 cites W2079931304 @default.
• W2000807900 cites W2086098710 @default.
• W2000807900 cites W2088725132 @default.
• W2000807900 cites W2089916171 @default.
• W2000807900 cites W2090910256 @default.
• W2000807900 cites W2118097956 @default.
• W2000807900 cites W2129494871 @default.
• W2000807900 cites W2188567254 @default.
• W2000807900 cites W2258690978 @default.
• W2000807900 cites W2596598505 @default.
• W2000807900 cites W3149726839 @default.
• W2000807900 cites W4251662319 @default.
• W2000807900 doi "https://doi.org/10.1111/j.1365-2125.1996.tb00107.x" @default.
• W2000807900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8951184" @default.
• W2000807900 hasPublicationYear "1996" @default.
• W2000807900 type Work @default.
• W2000807900 sameAs 2000807900 @default.
• W2000807900 citedByCount "57" @default.
• W2000807900 countsByYear W20008079002012 @default.
• W2000807900 countsByYear W20008079002013 @default.
• W2000807900 countsByYear W20008079002014 @default.
• W2000807900 countsByYear W20008079002015 @default.
• W2000807900 countsByYear W20008079002017 @default.
• W2000807900 countsByYear W20008079002018 @default.
• W2000807900 countsByYear W20008079002019 @default.
• W2000807900 countsByYear W20008079002021 @default.
• W2000807900 crossrefType "journal-article" @default.
• W2000807900 hasAuthorship W2000807900A5040883137 @default.
• W2000807900 hasConcept C118552586 @default.
• W2000807900 hasConcept C142724271 @default.
• W2000807900 hasConcept C204787440 @default.
• W2000807900 hasConcept C2775858608 @default.
• W2000807900 hasConcept C2776608144 @default.
• W2000807900 hasConcept C2776749334 @default.
• W2000807900 hasConcept C2777138316 @default.
• W2000807900 hasConcept C2777683783 @default.
• W2000807900 hasConcept C2778186239 @default.
• W2000807900 hasConcept C2778802184 @default.
• W2000807900 hasConcept C2779253243 @default.
• W2000807900 hasConcept C2780837902 @default.
• W2000807900 hasConcept C2781011581 @default.
• W2000807900 hasConcept C2781176495 @default.
• W2000807900 hasConcept C71924100 @default.
• W2000807900 hasConcept C98274493 @default.
• W2000807900 hasConceptScore W2000807900C118552586 @default.
• W2000807900 hasConceptScore W2000807900C142724271 @default.
• W2000807900 hasConceptScore W2000807900C204787440 @default.
• W2000807900 hasConceptScore W2000807900C2775858608 @default.
• W2000807900 hasConceptScore W2000807900C2776608144 @default.
• W2000807900 hasConceptScore W2000807900C2776749334 @default.
• W2000807900 hasConceptScore W2000807900C2777138316 @default.
• W2000807900 hasConceptScore W2000807900C2777683783 @default.
• W2000807900 hasConceptScore W2000807900C2778186239 @default.

• next